All Insights

AbbVie paid $2.1 billion for a biotech with no published human data. Here's what the science actually shows — and doesn't show — about whether the bet holds up.

Sam Altman says AI will transform education. The venture funding data tells a different story — the money goes to habit-forming practice apps, not tools that verify real learning. Meanwhile the US, EU, and China are running three genuinely different bets on how AI belongs in the classroom, and none of them are finished. This is a status check on where things actually stand, not another prediction piece.

Building AI sounds like something only a handful of billion-dollar labs can do. It isn't — using AI, building with it, fine-tuning it, and even training a narrow model from scratch are all realistic for one motivated person. This piece breaks down the five real levels of "building AI," with real companies (Cursor, Harvey, Sanofi, Microsoft) at each one, plus a step-by-step guide to building your own AI-powered tool this week.

While Mars gets the headlines, four governments are quietly racing to claim and defend a layer of infrastructure a few hundred kilometers overhead — and none of them are doing it entirely alone.

Americans favor real estate over stocks nearly two to one, even though stocks have the better long-run average return. This piece breaks down why leverage — not raw returns — explains the gap, then shows two realistic scenarios where the same framework produces opposite winners, and a third where the winner flips again depending on how long you hold. Includes what the model deliberately leaves out: taxes, liquidity, and active management effort.

U.S. health care spending hit $5.3 trillion in 2024 — more than any other country, despite the U.S. not even being the world's richest per capita. This piece breaks down the real reasons why (paperwork, physician pay, undernegotiated drug prices), how Germany, Japan, and Singapore keep costs down instead, which U.S. fixes are already underway, and where each of those dynamics creates a distinct opportunity for different types of investors.

Mega-caps spend billions like they know where the next wave is. They don't. Here's what buying drilling rights in pharma actually looks like — and why even the best-positioned players still miss almost every time.

A known disease. A known market. So why does pharma investing still feel like guessing? The answer splits cleanly into what you can actually predict — and what stays a coin flip no matter how good the science looks.

Roughly 97.5% of drug candidates die before a patent is ever filed on them — invisible to competitors, regulators, and the public. This piece breaks down how AI is starting to mine that hidden graveyard, and why no single unpatented failure has turned into a headline win yet.

Warren Buffett says he could still compound money at 50% a year. The data says the market that let him do that in the 1950s doesn't exist anymore — and here's the specific evidence why.